# OH2 Oncolytic Viral Therapy in Pancreatic Cancer

> **NCT04637698** · PHASE1,PHASE2 · TERMINATED · sponsor: **Binhui Biopharmaceutical Co., Ltd.** · enrollment: 5 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** OH2 injection

## Key facts

- **NCT ID:** NCT04637698
- **Lead sponsor:** Binhui Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-02-02
- **Primary completion:** 2023-05-04
- **Final completion:** 2023-05-04
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Strategy adjustment
- **Last updated:** 2023-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04637698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04637698, "OH2 Oncolytic Viral Therapy in Pancreatic Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04637698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*